2023.01.06
On January 6, 2023, Sichuan Biokin Pharmaceutical Co., Ltd. (“Biokin Pharmaceutical” or the “Company”, stock code: 688506) was listed on the Shanghai Stock Exchange STAR Market, raising a total amount of RMB 990.47 m. JunHe acted as legal counsel to the issuer in this project.
Biokin Pharmaceutical integrates the R&D, manufacturing and marketing of drugs and owns the business segments of various chemical and proprietary Chinese medicine preparations and biopharmaceuticals. It researches, develops and manufactures a full range of drugs, including small molecule chemical drugs, large molecule biological drugs, and antibody-drug conjugates (ADCs). By integrating its production experience and technological expertise in small molecule chemical drugs, as well as its platform technology and core competitive advantages in large molecule innovative biological drugs, the Company has built an innovative ADC development system with independent intellectual property rights and global interests. It has formed a “full chain integrated ADC R&D core technology platform,” a “flexible GMP standard multi-specific antibody and ADC manufacturing technology platform” and other core technology platforms. The Company has built a complete core technology support system and intellectual property protection framework, enabling it to independently and autonomously complete the whole process of innovative ADC research and development. It also has advantages in Payload development, coupling site development and targeted coupling technology.
JunHe was counsel to the issuer in this project, and has provided on-going and in-depth legal services to the Company since 2020. JunHe participated in the application for Biokin Pharmaceutical’s listing on the STAR Market. JunHe, in concert with the Company and other intermediaries, organized, demonstrated and standardized the many major and difficult legal issues, conducted pre-IPO tutoring and the application for listing, and replied to feedback from the Shanghai Stock Exchange and the China Securities Regulatory Commission. JunHe’s team was highly recognized by the Company and other intermediaries for its efficient and rigorous work style and meticulous and professional service attitude.
This project was led and undertaken by JunHe partners MA, Rui and TAO, Xudong with support from ZHAO, Jikui for the internal review.
